Genetic newborn screening and digital technologies: A project protocol based on a dual approach to shorten the rare diseases diagnostic path in Europe

Author:

Garnier Nicolas,Berghout JoanneORCID,Zygmunt Aldona,Singh Deependra,Huang Kui A.,Kantz Waltraud,Blankart Carl RudolfORCID,Gillner Sandra,Zhao Jiawei,Roettger Richard,Saier Christina,Kirschner JanORCID,Schenk Joern,Atkins Leon,Ryan Nuala,Zarakowska Kaja,Zschüntzsch JanaORCID,Zuccolo Michela,Müllenborn MatthiasORCID,Man Yuen-Sum,Goodman Liz,Trad Marie,Chalandon Anne Sophie,Sansen Stefaan,Martinez-Fresno Maria,Badger Shirlene,Walther van Olden Rudolf,Rothmann Robert,Lehner Patrick,Tschohl Christof,Baillon Ludovic,Gumus Gulcin,Gross Edith,Stefanov Rumen,Iskrov Georgi,Raycheva Ralitsa,Kostadinov KostadinORCID,Mitova Elena,Einhorn Moshe,Einhorn Yaron,Schepers Josef,Hübner MiriamORCID,Alves Frauke,Iskandar Rowan,Mayer RudolfORCID,Renieri Alessandra,Piperkova Aneta,Gut Ivo,Beltran Sergi,Matthiesen Mads Emil,Poetz Marion,Hansson Mats,Trollmann Regina,Agolini Emanuele,Ottombrino Silvia,Novelli AntonioORCID,Bertini Enrico,Selvatici Rita,Farnè MariannaORCID,Fortunato Fernanda,Ferlini AlessandraORCID

Abstract

Since 72% of rare diseases are genetic in origin and mostly paediatrics, genetic newborn screening represents a diagnostic “window of opportunity”. Therefore, many gNBS initiatives started in different European countries. Screen4Care is a research project, which resulted of a joint effort between the European Union Commission and the European Federation of Pharmaceutical Industries and Associations. It focuses on genetic newborn screening and artificial intelligence-based tools which will be applied to a large European population of about 25.000 infants. The neonatal screening strategy will be based on targeted sequencing, while whole genome sequencing will be offered to all enrolled infants who may show early symptoms but have resulted negative at the targeted sequencing-based newborn screening. We will leverage artificial intelligence-based algorithms to identify patients using Electronic Health Records (EHR) and to build a repository “symptom checkers” for patients and healthcare providers. S4C will design an equitable, ethical, and sustainable framework for genetic newborn screening and new digital tools, corroborated by a large workout where legal, ethical, and social complexities will be addressed with the intent of making the framework highly and flexibly translatable into the diverse European health systems.

Funder

European Union’s Horizon 2020 research and innovation programme and EFPIA

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference21 articles.

1. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database;S Nguengang Wakap;Eur J Hum Genet,2020

2. The Power of being counted in: Rare-X Website. https://rare-x.org/wp-content/uploads/2022/05/be-counted-052722-WEB.pdf, Accessed 29 December 2022.

3. How many rare diseases are there?;M Haendel;Nat Rev Drug Discov,2020

4. From scientific discovery to treatments for rare diseases—the view from the National Center for Advancing Translational Sciences—Office of Rare Diseases Research;P Kaufmann;Orphanet J Rare Dis,2018

5. EURORDIS Website. www.eurordis.org, Accessed 29 December 2022.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3